The DOI matches its Crossref record; 456 of the 456 references it cites were found in a registry or an index.
Neurobiological Similarities in Depression and Drug Dependence: A Self-Medication Hypothesis
Abstract
Epidemiological and clinical data indicate high comorbidity between depression and drug dependence that may reflect an attempt to self-medicate with drugs of abuse. The present review examines whether these two psychiatric disorders are related by attempting to identify similarities in the neurobiology of depression and drug dependence. Emphasis is put on the neuromechanisms that may mediate specific core symptoms of both disorders that reflect alterations in reward and motivational processes. First, the epidemiological and clinical data on the comorbidity of the two disorders are reviewed briefly. Then, the neuroadaptations associated with psychomotor stimulant, opiate, ethanol, nicotine, and benzodiazepine dependence in animals are reviewed. Finally, the neurotransmitter systems whose function appears to be altered in depression (i.e., serotonin, norepinephrine, acetylcholine, dopamine, gamma-aminobutyric acid, corticotropin releasing factor, neuropeptide Y, and somatostatin), as revealed primarily by animal studies, are discussed. It is concluded that drug dependence and depression may be associated with alterations in some of the same neurotransmitter systems and, in particular, with alterations of neurotransmitter function in limbic-related brain structures. Thus, these two psychiatric disorders may be linked by some shared neurobiology. Nevertheless, it remains unclear whether drug abuse and depression are different symptomatic expressions of the same preexisting neurobiological abnormalities, or whether repeated drug abuse leads to the abnormalities mediating depression (i.e., drug-induced depressions). The hypothesis of self-medication of non-drug- and drug-induced depressions with drugs of abuse is also discussed as a potentially important explanatory concept in understanding the observed clinical comorbidity of these two psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is believed that some depressed patients initiate smoking as an attempt to self medicate depressive symptoms with nicotine (Markou et al., 1998; Patton et al., 1998).”
From It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood (2008) · cites this paper as Markou et al., 1998
In the citing paper
“Depression and anxiety are both highly comorbid with nicotine dependence (Paperwalla et al., 2004), and nicotine use may be an attempt at self-medication in these conditions (Markou et al., 1998).”
From Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior (2010) · cites this paper as Markou et al., 1998
In the citing paper
“These findings suggest that chronic drug taking leading to hypo-activity of the meso-ventromedial striatal dopamine system may result in a negative mood state which in turn accelerates drug-taking (“self-medication”) in an attempt to improve the mood state (Markou et al., 1998).”
From Dopamine reward circuitry: Two projection systems from the ventral midbrain to the nucleus accumbens–olfactory tubercle complex (2007) · cites this paper as Markou et al., 1998
In the citing paper
“According to the self-medication hypothesis of nicotine dependence (Carmody, 1992; Markou, Kosten, & Koob, 1998; Pomerleau & Pomerleau, 1985), this might be because nicotine reduces negative affect and works as an antidepressant.”
From Nicotine addiction and psychiatric disorders (2015) · cites this paper as Markou et al., 1998
Citations
Cites
Items 401–456 of 456
Kling, M. A., Rubinow, D. R., Doran, A. R., Roy, A., Davis, C. L., Calabrese, J. R., Nieman, L. K., Post, R. M., Chrousos, G. P., & Gold, P. W. (2008) · Neuroendocrinology · doi:10.1159/000126345 · Cited by 30
Kosten, T. R., Rounsaville, B. J., Kosten, T. A., et al. (1991) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199107000-00002 · Cited by 30
Atterwill, C. K. (1980) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1980.tb03713.x · Cited by 30
Stressful Life Events Associated with Endogenous Depression
Cornell, D. G., Milden, R. S., & Shimp, S. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198508000-00003 · Cited by 30
Ingraham, L. J., & Wender, P. H. (1992) · Journal of Affective Disorders · doi:10.1016/0165-0327(92)90033-3 · Cited by 29
Idemudia, S. O. (1989) · Neuropsychopharmacology · doi:10.1016/0893-133x(89)90014-6 · Cited by 29
Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients
Rausch, J. L., Stahl, S. M., & Hauger, R. L. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90434-4 · Cited by 29
Owens, M. J., Vargas, M. A., & Nemeroff, C. B. (1993) · Journal of Psychiatric Research · doi:10.1016/0022-3956(93)90029-2 · Cited by 28
A Rating Scale for Assessment of Alcohol Withdrawal Psychopathology (AWIP)
Bokström, K., & Balldin, J. (1992) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1992.tb01370.x · Cited by 28
Anxiolytics and sedative/hypnotics dependence
Busto, U. E., & Sellers, E. M. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01760.x · Cited by 28
Byerley, W., McConnel, E. J., McCabe, R. T., et al. (1987) · Brain Research · doi:10.1016/0006-8993(87)91312-6 · Cited by 28
Scatton, B., Lloyd, K. G., Živković, B., et al. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-5347(25)00327-1 · Cited by 28
6. Psychosomatic Aspects of Movement Disorders
Cummings, J. L. (2015) · Advances in psychosomatic medicine · doi:10.1159/000411302 · Cited by 28
The cloning and sequence analysis of the rat serotonin-1A receptor gene
Fujiwara, Y., Nelson, D. L. G., Kashihara, K., Varga, E. V., Roeske, W. R., & Yamamura, H. I. (1990) · Life Sciences · doi:10.1016/0024-3205(90)90445-w · Cited by 27
Effects of antidepressant drug treatment on levels of NPY or prepro-NPY-mRNA in the rat brain
Bellmann, R., & Sperk, G. (1993) · Neurochemistry International · doi:10.1016/0197-0186(93)90011-s · Cited by 27
Nader, K., & van der Kooy, D. (1996) · Behavioral Neuroscience · doi:10.1037/0735-7044.110.2.389 · Cited by 27
Clinical Procedures for the Assessment of Abuse Potential
Henningfield, J. E., Johnson, R. E., & Jasinski, D. R. (1987) · Springer eBooks · doi:10.1007/978-1-4612-4812-5_27 · Cited by 26
Pilotto, R., Singer, G. H. S., & Overstreet, D. H. (1984) · Psychopharmacology · doi:10.1007/bf00427442 · Cited by 26
Role of serotonin in the regulation of β-adrenoceptors by antidepressants
Asakura, M., Tsukamoto, T., Kubota, H., et al. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90414-6 · Cited by 26
Stewart, R. B., Lemaire, G. A., Roache, J. D., & Meisch, R. A. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22756-2 · Cited by 26
Schedule induction of drug intake: differential responsiveness to agents with abuse potential.
Falk, J. L., & Tang, M. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23230-x · Cited by 26
Nader, K., & van der Kooy, D. (1996) · Behavioral Neuroscience · doi:10.1037//0735-7044.110.2.389 · Cited by 25
Manier, D. H., Gillespie, D. D., & Sulser, F. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90650-2 · Cited by 25
Intravenous self-administration of the short-acting benzodiazepine midazolam in the rat
Szostak, C., Finlay, J. M., & Fibiger, H. C. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90116-x · Cited by 25
Pl, P., Rezazadeh, S. M., & Lal, H. (1991) · PubMed · Cited by 25
Clinical and biochemical aspects of depressive disorders: III. Treatment and controversies
Caldecott-Hazard, S., & Schneider, L. S. S. (1992) · Synapse · doi:10.1002/syn.890100209 · Cited by 24
June, H. L., Murphy, J. M., Mellor-Burke, J. J., Lumeng, L., & Li, T. (1994) · Psychopharmacology · doi:10.1007/bf02245073 · Cited by 23
Willner, P. (1984) · Journal of Affective Disorders · doi:10.1016/0165-0327(84)90064-8 · Cited by 22
Peyrin, L., Pequignot, J. M., Chauplannaz, G., et al. (1985) · Journal of Neural Transmission · doi:10.1007/bf01252030 · Cited by 22
Sulser, F. (1983) · PubMed · Cited by 22
Wiech, N. L., & Rc, U. (1980) · PubMed · Cited by 22
Influence of imipramine on neuropeptide Y immunoreactivity in the rat brain
Śmiałowska, M., & Legutko, B. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90366-v · Cited by 21
Nelson, D. J., Pratt, G. D., PALMER, K., et al. (1991) · Neuropharmacology · doi:10.1016/0028-3908(91)90080-u · Cited by 21
Kakigi, T., Maeda, K., Kaneda, H., et al. (1992) · Journal of Affective Disorders · doi:10.1016/0165-0327(92)90078-k · Cited by 21
Nielsen, N. P., Cesana, B. M., Zizolfi, S., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb01402.x · Cited by 21
Mishra, R., & Sulser, F. (1978) · PubMed · Cited by 21
Desipramine does not alter plasma GABA in patients with major depression
Petty, F., Steinberg, J. L., Kramer, G. L., Fulton, M., & Moeller, F. G. (1993) · Journal of Affective Disorders · doi:10.1016/0165-0327(93)90119-5 · Cited by 20
Modulation of 5HT1A receptors in the hippocampus and the raphe area of rats treated with clonazepam
Lima, L., Salazar, M., & Trejo, E. J. (1993) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(93)90013-i · Cited by 20
Indoleamines in Depression and Suicide
van Praag, H. M. (1986) · Progress in brain research · doi:10.1016/s0079-6123(08)60642-1 · Cited by 19
Benzodiazepines increase preprocholecystokinin messenger RNA levels in rat brain
Rattray, M., Singhvi, S., Wu, P., Andrews, N., & File, S. E. (1993) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(93)90129-w · Cited by 19
Juergens, S. M. (1993) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30191-6 · Cited by 19
Andersson, K., Fuxé, K., Eneroth, P. H. E., Jansson, A., & H�rfstrand, A. (1989) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00736052 · Cited by 16
Symptom Comorbidity in Anxiety and Depressive Disorders
Copp, J., SCHWIDERSKI, U. E., & Robinson, D. S. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199006001-00011 · Cited by 16
Johnson, B. A., & Marzani-Nissen, G. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_17 · Cited by 13
GABAA Receptor Function and Expression following Chronic Ethanol and Barbiturate Administration
Morrow, A. L., Montpied, P., & Paul, S. M. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb33880.x · Cited by 13
Klimek, V., Nielsen, M. B., & Maj, J. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90551-5 · Cited by 13
Effects of acute and chronic desipramine treatment on somatostatin receptors in brain
Gheorvassaki, E. G., Thermos, K., Liapakis, G., et al. (1992) · Psychopharmacology · doi:10.1007/bf02245124 · Cited by 12
Cropper, M., Garner, A., Gd, M., Munt, D. F., La, R., Stevens, & Ac, B. (1987) · PubMed · Cited by 12
The psychopharmacology of GABA synapses: update 1989
Lloyd, K. G., Pichat, P., Scatton, B., et al. (1990) · Springer eBooks · doi:10.1007/978-3-7091-9050-0_3 · Cited by 10
Adenosine mechanisms are not affected by antidepressant concentrations of desipramine
Jonzon, B., & Fredholm, B. B. (1984) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1984.tb04892.x · Cited by 10
Intravenous and intragastric self-administration of chlordiazepoxide in the rat.
Davis, W. M., Smith, T. E., & Smith, S. G. (1987) · PubMed · Cited by 9
Rimón, R., Kultalahti, E. ‐., Kalli, A., et al. (1991) · Pharmacopsychiatry · doi:10.1055/s-2007-1014444 · Cited by 8
Papp, M. (1992) · European Neuropsychopharmacology · doi:10.1016/0924-977x(92)90021-y · Cited by 8
Pharmacological Approaches to Smoking Cessation
Robbins, A. S. (1993) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(18)30764-5 · Cited by 6
Basal Forebrain Involvement in Self-Administration of Drugs of Abuse
Porrino, L. J., Dworkin, S. I., & Smith, J. E. (1991) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-0145-6_19 · Cited by 3
Heavy Smokers, Smoking Cessation, and Clonidine: Results of a Double-blind, Randomized Trial
Glassman, A. H. (1988) · JAMA · doi:10.1001/jama.1988.03720190031026
Cited by
Sorted by citations
Koob, G. F., & Volkow, N. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.110 · Cited by 5,340
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
Ikemoto, S. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.05.004 · Cited by 1,477
Addiction and the brain antireward system
Koob, G. F., & Le Moal, M. (2008) · Annual Review of Psychology · doi:10.1146/annurev.psych.59.103006.093548 · Cited by 1,457
The association of cigarette smoking with depression and anxiety: a systematic review
Fluharty, M., Taylor, A. E., Grabski, M., & Munafò, M. R. (2017) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntw140 · Cited by 1,299
Metadata
- Authors
- Markou, A.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Markou, A
- Venue
- Neuropsychopharmacology
- Published
- 1998-03
- Volume
- 18
- Issue
- 3
- Pages
- 135-174
- ISSN
- 0893-133X (ISSN-L)
- OpenAlex
- W2042152382
- Cited by
- 767
- References
- 456
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 24 · 2023: 21 · 2022: 17 · 2021: 30 · 2020: 22 · 2019: 15 · 2018: 26 · 2017: 21 · 2016: 26 · 2015: 37 · 2014: 28 · 2013: 28 · 2012: 26
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50da004060-13)
- National Institute on Drug Abuse (DA 00213, DA04060, DA 00112)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, drug addiction, self-medication hypothesis, comorbidities, reward and motivation, neurotransmitter systems, limbic system, stimulant use disorder, opioid use disorder, ethanol dependence, nicotine dependence, benzodiazepine dependence, drug-induced depression, serotonin, norepinephrine, dopamine, GABA, neuropeptide Y, somatostatin, corticotropin-releasing factor
- MeSH terms
- Animals, Brain, Corticotropin-Releasing Hormone, Depressive Disorder, Neuropeptide Y, Norepinephrine, Serotonin, Comorbidity, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
